We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Favorable overall survival trend with pembrolizumab plus chemotherapy for endometrial cancer.
- Authors
Nierengarten, Mary Beth
- Abstract
A recent study presented at the Society of Gynecologic Oncology Annual Meeting on Women's Cancer found that the addition of pembrolizumab to chemotherapy significantly improved progression-free survival (PFS) in patients with endometrial cancer. The combination therapy showed favorable results for both mismatch repair deficient (dMMR) and mismatch repair proficient (pMMR) populations. The median PFS was 13.1 months in the pembrolizumab-chemotherapy group compared to 8.7 months in the chemotherapy alone group for pMMR patients, and the median PFS was not reached in the pembrolizumab-chemotherapy group for dMMR patients. The study also showed a non-significant trend of improvement in overall survival (OS) for both patient populations. These findings support the use of pembrolizumab in combination with chemotherapy as a first-line treatment for advanced or recurrent endometrial cancer.
- Subjects
ENDOMETRIAL cancer; OVERALL survival; CANCER chemotherapy; PEMBROLIZUMAB; GYNECOLOGIC oncology
- Publication
Cancer (0008543X), 2024, Vol 130, Issue 13, p2246
- ISSN
0008-543X
- Publication type
Article
- DOI
10.1002/cncr.35373